Branch retinal vein occlusion in a case of recalcitrant diffuse anterior scleritis treated with tofacitinib
Tóm tắt
A 47-year-old woman with hypertension and rheumatoid arthritis presented with non-necrotizing scleritis in both eyes. Despite a course of oral corticosteroids, she continued to experience persistent symptoms. A rheumatologist was consulted and initiated treatment with tofacitinib, a JAK/STAT inhibitor. Treatment with tofacitinib and oral corticosteroids resulted in an improvement in the scleritis in both eyes. However, a fundus examination of her left eye revealed a superior-temporal branch retinal vein occlusion. Given the growing concern regarding the increased risk of thromboembolic events with tofacitinib therapy, it is essential to consider the risk of retinal vascular occlusions when starting tofacitinib therapy, particularly in patients with underlying systemic comorbidities.
Tài liệu tham khảo
Pyare R, Kaushik V, Dutta Majumder P, Biswas J (2020) Tofacitinib in recalcitrant scleritis: first case report from India. Indian J Ophthalmol 68(9):1988–1990. https://doi.org/10.4103/ijo.IJO_534_20
Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ (2019) Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep 13:53–55. https://doi.org/10.1016/j.ajoc.2018.12.001
Pyare R, Dutta Majumder P, Shah M, Kaushik V, Agarwal M, Biswas J (2022) Tofacitinib in Scleritis: a Case Series. Ocul Immunol Inflamm Published online September 20:1–7. https://doi.org/10.1080/09273948.2022.2113805
Dhillon S, Tofacitinib (2017) A review in rheumatoid arthritis. Drugs 77(18):1987–2001. https://doi.org/10.1007/s40265-017-0835-9
Pfizer (2023) PHASE 3B/4 Randomized safety endpoint study of 2 doses of tofacitinib in comparison to a tumor necrosis factor (TNF) INhibitor in subjects with rheumatoid arthritis. clinicaltrials.gov; 2021. Accessed April 3, https://clinicaltrials.gov/ct2/show/NCT02092467
Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 386(4):316–326. https://doi.org/10.1056/NEJMoa2109927
Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase - PubMed. Accessed 5 April 2023. https://pubmed.ncbi.nlm.nih.gov/32533433/
Mori S, Ogata F, Tsunoda R (2021) Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review. Clin Rheumatol 40(11):4457–4471. https://doi.org/10.1007/s10067-021-05911-4
Winthrop KL, Baddley JW, Chen L et al (2013) Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 309(9):887–895. https://doi.org/10.1001/jama.2013.1099
Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL (2016) Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis 75(10):1843–1847. https://doi.org/10.1136/annrheumdis-2016-209131
Curtis JR, Lee EB, Kaplan IV et al (2016) Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis 75(5):831–841. https://doi.org/10.1136/annrheumdis-2014-205847
Wollenhaupt J, Silverfield J, Lee EB et al (2014) Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol 41(5):837–852. https://doi.org/10.3899/jrheum.130683